A phase I safety study of topical calcitriol (BPM31543) for the prevention of chemotherapy-induced alopecia.

Mario E LacoutureHedy DionShobha RavipatyJoaquin J JimenezKhampaseuth ThapaEric M GrundEly BenaimNikunj TannaShen LuanNathaniel DiTommasoNiven R NarainRangaprasad SarangarajanElder GrangerBrian BermanShari B Goldfarb

Published in: Breast cancer research and treatment (2020)

BPM31543 applied topically twice daily to the scalp is safe and well tolerated in patients receiving taxane-based chemotherapy. No DLT was observed at up to 80 µg/mL, and MTD was not reached. Based on the data from this trial, BPM31543 represents a promising therapy and warrants further investigation in Phase 2/3 trials.

Keyphrases

chemotherapy induced
clinical trial
study protocol
electronic health record
big data
locally advanced
phase iii
randomized controlled trial
stem cells
phase ii
squamous cell carcinoma
rectal cancer
mesenchymal stem cells
data analysis